A  enhancer-driven HSV thymidine kinase-expressing vector for controlling occult peritoneal dissemination of gastric cancer cells by unknown
Saeki et al. BMC Cancer  (2015) 15:439 
DOI 10.1186/s12885-015-1436-1RESEARCH ARTICLE Open AccessA GSDMB enhancer-driven HSV thymidine kinase-
expressing vector for controlling occult peritoneal
dissemination of gastric cancer cells
Norihisa Saeki1*, Rie Komatsuzaki2, Fumiko Chiwaki2, Kazuyoshi Yanagihara3 and Hiroki Sasaki2*Abstract
Background: Gastric cancer (GC) is one of the major malignant diseases worldwide, especially in Asia, and Japan
and Korea have the highest incidence in the world. Because most of the cases that are refractory to therapies die
due to peritoneal dissemination (PD) of the cancer cells, controlling PD is important for patient survival. GSDMB is a
member of the gasdermin gene family. Because GSDMB is expressed in many types of cancer, including GC, it is
likely that the gene contains a regulatory region that is utilized for therapy of occult PD through cancer cell-specific
expression of cytotoxic genes.
Methods: We performed reporter assays to identify the regulatory region for the cancer cell-specific expression. We
also constructed a lentiviral therapeutic vector that expresses herpes simplex virus thymidine kinase (HSVtk) in a GC
cell-specific manner, and tested it in a mouse model of PD.
Results: We identified the regulatory region at +496 to +989 from the GSDMB transcription start site and
designated it as a GSDMB enhancer. The lentiviral therapeutic vector suppressed proliferation of a GC cell line,
60As6, in vitro in the presence of ganciclovir, and intraperitoneal administration of the vector prolonged the survival
term of mice that were intraperitoneally inoculated with 60As6 one week prior to the administration.
Conclusions: The GSDMB-driven HSVtk expression vector had a therapeutic effect on the occult PD model mice.
This strategy can potentially be used to treat GC patients with PD.
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Gastric cancer (GC) is one of the major malignant dis-
eases, especially in Asia, and the second leading cause of
cancer-associated deaths worldwide [1]. It is usually classi-
fied into two types (Lauren’s classification) [2], intestinal
and diffuse, which are thought to reflect its pathogenesis
[3]. The diffuse-type GC (DGC) is sub-classified as poorly
differentiated GC (non-solid type) or undifferentiated GC
in the Japanese Gastric Cancer Association classification
system [4]. DGC is infiltrative and often shows aggressive
invasion into the gastric wall, resulting in metastasis and* Correspondence: nsaeki@ncc.go.jp; hksasaki@ncc.go.jp
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unless otherwise stated.the spread of GC cells into the peritoneal cavity (periton-
eal dissemination, PD).
The disseminated GC cells in the peritoneal cavity give
rise to peritoneal carcinomatosis (PC) [5]. PC causes
gastrointestinal symptoms, such as abdominal pain, nau-
sea and vomiting, as well as systemic symptoms such as
weight loss and ascite. PC not only strongly deteriorates
the quality of life of GC patients, but it is also the lead-
ing cause of death in GC [6]. With supportive care
alone, the median survival of patients with PC is 3–6
months [7]. If treated with systemic chemotherapy, in
the same manner as for other metastatic lesions, PC
shows a poorer response to the therapy than other types
of metastasis in GC, mainly because of poor distribution
of the chemotherapeutic agent in the peritoneal cavity.
Therefore, recent efforts have focused on innovative PC
therapeutics, such combining of cytoreductive surgery,his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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These combined approaches have slightly improved the
prognosis of PC, although the median survival period is
still less than 12 months, making it clear that there is a
practical limit to the efficacy of surgical cytoreduction
[8, 9]. Recent studies suggest that it is important to iden-
tify GC patients with occult PD by performing a cyto-
logic examination of peritoneal lavage fluid, because
such cases showed improved prognosis if they obtained
conversion to negative cytology by extensive intraopera-
tive peritoneal lavage followed by intraperitoneal chemo-
therapy [10].
The concept of “suicide gene” cancer therapy, using
herpes simplex virus thymidine kinase (HSVtk), emerged
in the 1980s [11]. HSVtk catalyzes the phosphorylation
of the guanosine analogue ganciclovir (GCV) into a
monophosphate form that is subsequently phosphory-
lated by cellular nucleotide kinases into highly toxic
ganciclovir triphosphate [12]. Ganciclovir triphosphate
blocks DNA replication, leading to cell cycle arrest and
cell death [13]. Therapy involving HSVtk transfer into
cancer cells, followed by GCV administration, is known
as suicide gene therapy, and this technique was recently
used in a phase III clinical trial on glioblastoma multi-
forme [12].
In this study, we developed a therapeutic vector that
expresses HSVtk in cancer cells, utilizing a regulatory
region of the gasdermin B gene (GSDMB). GSDMB is a
member of the gasdermin (GSDM) family that consists
of four genes, GSDMA, GSDMB, GSDMC and GSDMD
[14, 15], and is expressed in proliferating cells of normal
epithelium and also in many types of cancer, including
esophageal, gastric, liver, colon, uterine cervix and
breast cancers [14, 16–18]. GSDMB expression is driven
by two promoters, the cellular promoter and LTR-derived
promoter [19–21]. The LTR-derived promoter (LTR pro-
moter) is active in most normal tissues, except the stomach,
and in many cancer cell lines, while the cellular promoter is
active in normal stomach tissue and in some cancer cell
lines [20]. In this study, we identified a region in down-
stream of the LTR promoter, that showed strong transcrip-
tional activity in GC cell lines. We used this region to




Gastric cancer (GC) tissues were provided by the National
Cancer Center Hospital after obtaining written informed
consent from each patient, which was approved by the
National Cancer Center Institutional Review Board (ID:
No.17-030). Tissue specimens were immediately frozen
with liquid nitrogen after surgical extraction, and stored
at −80 °C until use.Microarray analysis
Total RNA was isolated by suspending the cells in ISO-
GEN lysis buffer (Nippon Gene, Toyama, Japan) followed
by precipitation with isopropanol. We performed expres-
sion analyses using Human Expression Array U95A ver-
sion 2 (Affymetrix, Santa Clara, CA) according to the
suppliers’ protocols . The expression value (average differ-
ence: AD) of each gene was calculated using GeneChip
Analysis Suite version 4.0 software (Affymetrix). Hierarch-
ical clustering of microarray data was performed using
GeneSpring (Agilent Technologies Ltd., Palo Alto, CA),
Microsoft EXCEL, and Cluster & TreeView [22, 23]. All
microarray data have been deposited in a MIAME com-
pliant database, GEO (accession number; GSE47007).
By Wilcoxon u-test (p < 0.05) and by showing a 2-fold
change, genes expressed specifically in diffuse-type GC
were selected [22].
Cell lines and primary culture of mouse mesothelial cells
Three gastric cancer cell lines, HSC-57, derived from
intestinal-type GC, and HSC-59 and HSC-60, both de-
rived from diffuse-type GC, were established and charac-
terized by one of the authors [24]. SNU16, derived from
diffuse-type GC, was provided from the American Type
Culture Collection (ATCC), Two other cell lines with ef-
ficiency in producing PD mice, 60As6 and 60As6GFP
(60As6 expressing green fluorescence protein), were
established by the authors from the diffuse-type GC
derived HSC-60 cell line after several passages of intra-
peritoneal transplantation to mice [25]. CC-2511, a
fibroblast cell line, was purchased from Lonza, Japan
(Tokyo, Japan). All cell lines were maintained in Dulbec-
co’s Modified Eagle Medium. Mouse mesothelial cells
were harvested by injection of 10 mL of warmed 0.25 %
Trypsin/EDTA solution into the peritoneal cavity [26].
The cells were incubated for 3 days in RPMI-1640 sup-
plemented with L-glutamine, Phenol Red and HEPES
(WAKO, Tokyo, Japan). Met-5A, a human mesothelial
cell line, was provided by ATCC and maintained in
Medium 199 (Life Technologies, Tokyo, Japan) supple-
mented with 3.3 nM EGF (Life Technologies), 400 nM
hydrocortison (Sigma-Aldrich, St. Louis, MO USA), 870
nM Insulin (Life Technologies) and 10 % FBS.
RT-PCR
Total RNAs from human normal organs were purchased
from BioChain, Hayward, CA. Total RNAs were extracted
using an RNeasy Mini kit (QIAGEN, Tokyo, Japan). After
generating first-strand cDNA from total RNA using Ther-
moScript RT-PCR System (Life Technologies, Tokyo
Japan), PCR was performed with AccuPrime™ Pfx DNA
Polymerase (Life Technologies) under the following cycling
conditions of either 35 (LTR transcripts) or 25 cycles
(others): 95 °C for 1 min; 56 °C (β-actin) or 58 °C (others)
Saeki et al. BMC Cancer  (2015) 15:439 Page 3 of 9for 1 min; and 72 °C for 1 min. The following primer
sets were used: for cellular promoter transcript, 5′-
CTTCCTGAGATTCAGAGGCC-3′ and 5′-CCAGAATT
TGAAACTCAGCC-3′; for LTR promoter-derived tran-
scripts, 5′-TTCAGTTGCTTCAGGCCATC-3′ and 5′-CC
AGAATTTGAAACTCAGCC-3′; for the 3′ side of GSD
MB, 5′-ATTCTGGACTTCCTGGATGC-3′ and 5′-ATGT
ATGAAATCCAGGCTGG-3′; for MYH11, 5′- CAGTGA
CGATGAGAAGTTCC-3′ and 5′- CGCAGAAGAGGC
CAGAGTAC; and for β-actin, 5′-TCATCACCATTGG
CAATGAG-3′ and 5′-CACTGTGTTGGCGTACAGGT-3′.
Reporter Assay
A genomic fragment, from −1080 to +1053 of GSDMB and
containing the LTR promoter, was amplified by PCR using
LA Taq Hot Start DNA polymerase (Takara) in 35 cycles of
96 °C for 30 s and 68 °C for 2 min, using primer sets: 5′-
CTTCCTGAGATTCAGAGGCC-3′ and 5′-CTCGAGTT
CACTGTGTTAGCCAGG-3′, and inserted into a pGL3
basic vector (Promega, Madison, WI). It was truncated
using the restriction sites: Nhe I and EcoR I to generate
the −1035 to +1053 fragment; KpnI and EcoR I for −426
to +1053; Nhe I and Afl II for −61 to +1053; Nhe I and
Eco81 I for +129 to +1053; and Nhe I and Stu I for +496
to +1053. The +496 to +1053 reporter construct was
further truncated with restriction enzymes: Nhe I and
Swa I for +757 to +1053; Nhe I and Pvu II for +860 to
+1053; Nhe I and BstX I for +989 to +1053; Xho I and
BstX I for +496 to +989; Xho I and Pvu II for +496 to
+860; and Xho I and Swa I for +496 to +757. For further
truncation of the +496 to +989 fragment, PCR was per-
formed with the fragment as a template using Ex Taq
DNA polymerase (Takara) in 35 cycles of 95 °C for
1 min, 58 °C for 1 min, and 72 °C for 1 min, using the
following primer sets: for +562 to +989, 5′-GCTAGCT
GTGGGATTTGTACACATCC-3′ and 5′- AGATCTCGA
CTGGGATTACAGG-3′; and for +649 to +989, 5′-GCTA
GCTTTATTTCCACTGGAAACCG-3′ and 5′-AGATCTC
GACTGGGATTACAGG-3′. After amplification, fragments
were inserted into pGL4.12[luc2CP] vector (Promega).
The −1 kb upstream regions of CXCR4 and CXCR7 were
prepared by genomic PCR using MightyAmp DNA
polymerase (Takara) in 35 cycles of 98 °C for 10 s, 62 °C
for 15 s, and 68 °C for 2 min, using the following primer
sets: for CXCR4, 5′-GCTAGCGCGCCCACTGCAAAC
CTCAG-3′ and 5′-CTTAAGTCACTTTGCTACCTGC
TGC-3′; and for CXCR7, 5′-GCTAGCCGGAGGCCC
CCGGAGAGCAG-3′ and 5′-CTTAAGTTTGCAACA
ACTGTGAGC-3′. These fragments were inserted into
the pGL4.12[luc2CP] vector. One microgram of each
construct and the Renilla luciferase control reporter
vector (pRL-SV40 vector, Promega) were co-transfected
into 1 × 105 cells using SuperFect Transfection Reagent
(QIAGEN). The luciferase assay was performed 24 hafter the reporter introduction, using a Dual-Luciferase
Reporter Assay System (Promega). The assay was car-
ried out in triplicate.GSDMB enhancer-HSVtk lentivirus vector
A pMFG-HSVtk vector was provided by RIKEN BRC
through the National Bio-Resource Project of the MEXT,
Japan, by courtesy of Dr. Hirofumi Hamada, and an
HSVtk cDNA was excised from it as an Nco I-BamH I
fragment. To construct the GSDMB enhancer-HSVtk
lentivirus vector, first the +496 to +989 fragment
(GSDMB enhancer) was inserted into pcDNA3.1 (+)
(Life Technologies) between Nhe I and Hind III sites,
and then HSVtk cDNA was inserted into the vector at a
BamH I site in the forward (for sense-strand expression)
or reverse (for antisense-strand expression) direction.
Next, GSDMB enhancer-HSVtk sense and GSDMB
enhancer-HSVtk antisense fragments were excised
from the plasmid vectors as Nhe I-Not I fragments and
inserted into pLVSIN-CMV neo vectors between the Xba
I and Not I sites. Finally, a CMV promoter was removed
from the lentiviral constructs. To generate viral particles
containing the vectors, the constructs were introduced
into Lenti-X™ 293 T Cells (Takara) using Lenti-X™ HTX
Packaging System (Takara). After 72 h’-incubation, the
medium was collected and the viral titer (cfu/mL) was
determined by transduction into HT-1080 cells in the
presence of polybrene (5 μg/mL in culture medium,
Sigma-Aldrich). The particles were applied to Met-5A and
60As6 (1 × 105 cells per dish, in triplicate) in vitro in the
presence of polybrene (5 μg /mL), and the cells were incu-
bated in medium containing Gancicrovir (GCV, 5 μg/mL,
WAKO) for 5 days for cell growth assays. The assays were
performed in triplicate and P-value of Student’s t-test
between the cultured cells with (+) and without (−) GCV
was calculated.Treatment of PD mouse model with GSDMB enhancer-HSVtk
vectors
We previously reported a mouse PD model (PD mice)
that was produced by intraperitoneal injection of 60As6
cells [25]. 60As6GFP cells (1 × 106 cells per mouse) were
injected into the peritoneal cavity of 18 mice (6 week-
old mice of CB17/Icr-Prkdc < scid>/CrlCrlj Genotype:
scid/scid, Charles River, Yokohama Japan) at day 1. The
mice were divided into two groups; one group was
injected with the antisense expression vector, and the
other group was injected with the sense vector; both
groups then were intraperitoneally injected with 2 mL of
PBS solution containing viral particle (5 × 105 cfu) and
Ganciclovir (2 mg) at 8, 10 and 12 day. The mean sur-
vival time of each group and the P-value of Student’s
t-test between the two groups were calculated. The study
Saeki et al. BMC Cancer  (2015) 15:439 Page 4 of 9was approved by the National Cancer Center Committee
on Animal Experiments.
Results
Identification of an enhancer region in GSDMB, which
drives gene expression in GC cells
To identify the promoter/enhancer regions that would
be effective in the development of a therapeutic vector
for peritoneal dissemination (PD), we first searched for
genes more frequently expressed in diffuse-type GC than
in intestinal-type GC using comparative gene expression
analysis between 12 primary diffuse-types and 18 intestinal-
types, because PD is more frequently seen in diffuse-type
GC than in the intestinal-type [22]. We noticed that four of
ten Affymetrix GeneChip probe sets showing the highest
fold-change for gene expression in diffuse-type GC com-
pared to intestinal-type were probe sets for MYH11 (my-
osin, heavy chain 11, smooth muscle gene, Additional file 1:
Table S1). After confirming that the gene is not expressed
in the immortalized human mesothelial cell line MeT-5A
(data not shown), we selectedMYH11 as a strong candidate
for the gene whose promoter enables diffuse-type GC spe-
cific expression of HSVtk. However, the gene is notA
B
C
Fig. 1 GSDMB gene is transcribed by the Cellular and LTR promoters. (a) A sch
one by cellular promoter and the other by LTR, in human normal tissues (RT-P
variant 1 (NM_001042471), variant 2 (NM_018530), variant 3 (NM_001165958) a
driven by the cellular promoter and that of variant 2 is by the LTR promoter. T
LTR transcripts in gastric cancer tissues, 15 intestinal-type and 15 diffuse-type sexpressed in 60As6 cells that were used for making PD
model mice (Additional file 2: Figure S1). It is likely that
MYH11 is expressed in cancer-associated fibroblasts which
are especially abundant in diffuse-type GC tissues. Next,
going out of the microarray data analysis, we shifted our at-
tention to upstream regions of CXCR4 (chemokine (C-X-C
motif) receptor 4 gene) and CXCR7 (chemokine (C-X-C
motif) receptor 7 gene), as both are expressed in many
types of cancer and have an important role in metastasis
[27]. However, using reporter assays, we found that the up-
stream regions of these genes were transcriptionally active
in both the MeT-5A and the 60As6 cells (Additional file 2:
Figure S2), implying that the regions drive the expres-
sion of HSVtk in human mesothelial cells in vivo. Fi-
nally, we focused on the GSDMB gene, as our previous
study indicated that it is strongly expressed in GC tis-
sues and cell lines [14].
GSDMB is transcribed by two promoters, cellular and
LTR promoters (Fig. 1a), and the latter is mainly used in
normal tissues and in cancer cell lines [19–21]. We con-
firmed these findings by performing RT-PCR analyses
on RNA from several types of normal tissues (Fig. 1b).
RT-PCR on GC surgical specimens demonstrated thatematic illustration of the two promoters. (b) Expression of two transcripts,
CR). Four variants of human GSDMB transcript are registered in GenBank;
nd variant 4 (NM_001165959). Transcription of variants 1, 3 and 4 is
he 3′ side of the GSDMB transcripts is common to each. (c) Expression of
amples (RT-PCR on surgical specimens)
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GCs and in 11 of 15 diffuse-type GCs (Fig. 1c).
To identify a region critical for the transcriptional activity
in GC cells, a DNA fragment spanning −1080 to +1053 bp,
the position from a transcription start site for the LTR pro-
moter, was isolated (Fig. 2a). The reporter assays on trun-
cated DNA fragments using two GC cell lines, HSC-57 and
HSC-59, indicated that a +496 to +989 region had strong
transcriptional activity, even stronger than that of the ori-
ginal −1080 to +1053 fragment, and that further truncation
of the +496 to +989 fragment resulted in significant
reduction of the transcriptional activity (Fig. 2b). TheA
B
Fig. 2 Identification of GSDMB enhancer. (a) A schematic illustration showing
(LTR) element of human endogeneous retrovirus is shown by a double-heade
of the LTR promoter. (b) Luciferase assays using two gastric cancer cell lines, H
spanning from +496 to +989, which was designated as GSDMB enhancer. Vecregion corresponding to this fragment with strong tran-
scriptional activity was named GSDMB enhancer.
Construction of a GSDMB enhancer-driven HSVtk lentivirus
vector
We previously reported a mouse PD model (PD mice)
that was produced by intraperitoneal injection of 60As6
cells [25]; in this study, we developed a viral therapeutic
vector for the treatment of PD mice. For examining the
strength of the transcriptional activity of GSDMB enhan-
cer in 60As6, reporter assays were performed, using the
reporter construct for the upstream regions of CXCR4reporter constructs used in the luciferase assays. Long terminal repeat
d arrow. The position is from the transcription start site for the transcript
SC-57 and HSC-59, revealed a region with strong transcriptional activity,
tor, empty reporter vector, Bar, standard deviation
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showed stronger transcriptional activity in 60As6 cells
than the CXCR4 or the CXCR7 upstream regions, and,
importantly, the GSDMB enhancer had very weak tran-
scriptional activity in mouse peritoneal mesothelial cells
and in Met-5A, a human mesothelial cell line (Fig. 3).
This result suggests that the GSDMB enhancer enables
HSVtk expression almost exclusively in 60As6 but not in
mesothelial cells of the peritoneal cavity of the PD mice,
and probably not in human peritoneal mesothelium.
Next, we examined the effect of the HSVtk/GCV ther-
apy using the GSDMB enhancer-driven HSVtk lentivirus
vector on 60As6 in vitro (Fig. 4a). The number of 60As6
cells transduced with the lentivirus vector was significantly
reduced when incubated in medium supplemented withFig. 3 GSDMB enhancer has strong transcriptional activity in a 60As6
cell line. Luciferase assays with three types of cultured cells: 60As6
cells that were used for making peritoneal dissemination (PD) model
mice in this study, primary culture cells of mouse peritoneal mesothelial
cells and established human mesotherial cell line Met-5A. Bar,
standard deviationGCV; on the other hand, the same HSVtk/GCV treatment
had no effect on the cell number of Met-5A (Fig. 4b).HSVtk/GCV therapy of occult PD mice
We applied HSVtk/GCV therapy to PD mice. In this
therapeutic assay, we prepared two types of the GSDMB
enhancer-driven lentivirus vector: one vector expressed
the sense-strand of HSVtk cDNA and was used for the
treatment of PD mice, whereas the other vector
expressed the antisense-strand and was used as the con-
trol. The therapy was started seven days after intraperi-
toneal inoculation of 60As6 cells expressing green
fluorescence protein (60As6GFP). This regimen was de-
signed for treatment of occult PD model in which
60As6GFP cells were diffusely engrafted into the peri-
toneal cavity (Figs. 4c, d). After three doses of treatment,
at day 36, none of the nine mice treated with HSVtk
sense-expression vector had died, while two of the nine
reference mice had already died. None of the nine refer-
ence mice were alive at day 57, i.e., eight weeks after
injection of 60As6GFP cells; however, four of nine thera-
peutic vector-treated mice were still alive (Fig. 4e). This
result suggests that the therapy can improve the prognosis
of occult PD mice.Discussion
The GSDMB enhancer drives gene expression in GC cells
Previously we reported that GSDMB is expressed in all
GC tissues and cell lines examined [14], and in this
study we demonstrated that the LTR promoter drives
GSDMB expression in 25 of 30 GC specimens (Fig. 1c).
The transcriptional activity of the LTR region (Fig. 2a)
was previously demonstrated by reporter assays in non-
GC cell lines [20, 21]. However, we found a distinct
region with strong transcriptional activity in the down-
stream of the LTR region, and designated it as GSDMB
enhancer. In addition to the two GC cell lines, HSC-57
and HSC-59, the transcriptional activity of this region
was detected by reporter assays in other GC cell lines,
including MKN74 (relative luciferase activity was ap-
proximately 1.9), HSC-60 (29.4), HSC-42 (2.5) and HSC-
44 (4.6), but not in HSC-58 or MKN28 (data not shown)
[14]. Thus, the GSDMB enhancer does not drive gene
expression in some GC cells.
Truncation of a region spanning +496 to +562 signifi-
cantly reduced the transcriptional activity of the GSDMB
enhancer (Fig. 2b, +562 to +989). In the +496 to +562
region, we found consensus-binding sites of several tran-
scription factors, including GATA2, GATA3, GATA4,
YY1, SOX5, SOX9, SOX10 and NFY-A, and base-
substitution in any of these consensus sequences did not
affect the transcriptional activity of the enhancer (data




Fig. 4 HSVtk/GCV therapy using the GSDMB enhancer-driven lentivirus vector improved the survival rate of PD mice. (a) A lentiviral therapeutic
vector for GSDMB enhancer (Enh)-driven expression of herpes simplex virus thymidine kinase (HSVtk). (b) Cell proliferation assays on 60As6 and
Met-5A transduced with the therapeutic vector, performed by incubation in the medium with (+)/without (−) ganciclovir (GCV). (c) A regimen of
HSVtk/GCV therapy for PD mice. Bar, standard deviation, P, P -value of Student’s t-test between the cultured cells with (+) and without (−) GCV.
(d) Microscopic observation exhibited a small population of 60As6GFP cells (green fluorescence) implanted into mouse peritoneum at day 10.
(e) Number of survived mice after HSVtk/GCV therapy with the sense-strand expressing vector (red) and with an antisense-strand expressing vector as
reference (blue). Mean survival time of each group is shown at the right side with P- value of Student’s t-test between the two groups
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has not yet been identified.
Application of the therapeutic lentivirus vector to
treatment of human occult PD
Curative therapy has not been established for PD. GC
patients with macroscopic PD have poor prognoses, with
a median overall survival of 3–6 months. Those with
only microscopic PD also have a poor prognosis; their
5-year survival rate is 0-18 % [28]. Therefore, it is im-
portant to detect occult PD by cytologic examination of
peritoneal lavage fluid and completely eradicate cancer
cells in the peritoneal cavity. Meta-analyses by Cabalaget al. indicated that extensive intraperitoneal lavage
(EIPL, physiological saline 1 litter/dose, 10 times) and
intraoperative intraperitoneal chemotherapy (IIPC) with
cisplatin significantly improved 5-year overall survival to
more than 40 % [28]. The results of our study suggest
that HSVtk/GCV therapy using the lentivirus vector im-
proves the prognosis of patients independently, and we
assume it will be used as a consolidation therapy. Solid
tumors with diffuse growth are composed of many myo-
fibroblasts and few vessels (e.g., diffuse-type GCs, pan-
creatic cancers and scirrhous type of breast cancer).
Depending on the conditions of the microenvironment,
such as nutrient deficiency, these tumors show a high
Saeki et al. BMC Cancer  (2015) 15:439 Page 8 of 9prevalence of rarely-proliferative tumor cells. Thus, diffuse-
type GC cells disseminated in the peritoneal cavity may
consist of a population that can resist the cytotoxic effect of
cisplatin. The lentivirus therapeutic vector can introduce
HSVtk into both proliferating and non-proliferating cells.
Moreover, the GSDMB enhancer enables GC cell-specific
HSVtk expression. This restricted expression minimizes
mesothelial cell damage, implying that the gene therapy can
be performed using doses high enough to completely eradi-
cate GC cells, even those resistant to cisplatin, in occult
PD. It is likely that combination therapy, EIPL and IIPC,
followed by HSVtk/GCV therapy using the lentivirus vec-
tor, will improve the prognosis of occult PD more signifi-
cantly than the EIPL and IIPC combination therapy alone.
We believe that this regimen is worthy of being placed on
clinical trials. Although it appears that the GSDMB enhan-
cer does not work in some GC cells, further studies aiming
at identifying additional GC-specific enhancers, will resolve
this problem.Conclusions
The GSDMB-driven HSVtk expression vector had a thera-
peutic effect on the occult PD model mice. This strategy
can potentially be used to prevent GC patients from con-
tracting PD and also used to treat GC patients with PD.Additional files
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specific to diffuse-type gastric cancer.
Additional file 2: Figure S1. MYH11 is not expressed in gastric cancer
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